• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重新审视平衡评估系统。

Balanced assessment systems revisited.

作者信息

Dankó Dávid, Molnár Márk Péter

机构信息

Institute of Management, Corvinus University of Budapest, Budapest, Hungary.

Ideas & Solutions, Budapest, Hungary.

出版信息

J Mark Access Health Policy. 2017 Jul 26;5(1):1355190. doi: 10.1080/20016689.2017.1355190. eCollection 2017.

DOI:10.1080/20016689.2017.1355190
PMID:28804602
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5533122/
Abstract

In 2014, balanced assessment systems (BAS) were proposed as a resource-conscious, 'fit-for-purpose' form of health technology assessment for middle-income countries which lack resources and competences necessary for resource-intensive health technology assessment models. BAS has undergone extensive policy debate in the period since its publication but it has not been critically assessed in a structured form yet. This article aims to describe both the contributions and the weak spots of the original framework and to reflect on them with the intention of further developing the model.

摘要

2014年,平衡评估系统(BAS)被提议作为一种资源节约型、“适用”的卫生技术评估形式,用于缺乏资源密集型卫生技术评估模式所需资源和能力的中等收入国家。自发布以来,BAS在这段时间里经历了广泛的政策辩论,但尚未以结构化形式进行严格评估。本文旨在描述原始框架的贡献和弱点,并对其进行反思,以期进一步完善该模式。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c61/5533122/c7c7b35421f6/zjma_a_1355190_f0002_b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c61/5533122/4bb3520cc063/zjma_a_1355190_f0001_b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c61/5533122/c7c7b35421f6/zjma_a_1355190_f0002_b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c61/5533122/4bb3520cc063/zjma_a_1355190_f0001_b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c61/5533122/c7c7b35421f6/zjma_a_1355190_f0002_b.jpg

相似文献

1
Balanced assessment systems revisited.重新审视平衡评估系统。
J Mark Access Health Policy. 2017 Jul 26;5(1):1355190. doi: 10.1080/20016689.2017.1355190. eCollection 2017.
2
Health technology assessment in middle-income countries: recommendations for a balanced assessment system.中等收入国家的卫生技术评估:关于建立平衡评估体系的建议
J Mark Access Health Policy. 2014 Mar 11;2. doi: 10.3402/jmahp.v2.23181. eCollection 2014.
3
Multicriteria decision analysis (MCDA) for health technology assessment: the Queensland Health experience.用于卫生技术评估的多标准决策分析(MCDA):昆士兰卫生部门的经验
Aust Health Rev. 2019 Oct;43(5):591-599. doi: 10.1071/AH18042.
4
An Evidence Framework for Off-Patent Pharmaceutical Review for Health Technology Assessment in Emerging Markets.新兴市场卫生技术评估中专利过期药品审查的证据框架
Value Health Reg Issues. 2018 Sep;16:9-13. doi: 10.1016/j.vhri.2018.01.003. Epub 2018 Mar 30.
5
Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging Markets.应用多标准决策分析(MCDA)简单评分法作为一种基于证据的卫生技术评估方法,用于评估新兴市场中的非专利药品(OPPs)。
Value Health Reg Issues. 2017 Sep;13:1-6. doi: 10.1016/j.vhri.2017.02.001. Epub 2017 May 11.
6
Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.将健康技术评估(HTA)与多准则决策分析(MCDA)相结合,以实现高效的医疗保健决策:将 EVIDEM 框架应用于药品评估。
Med Decis Making. 2012 Mar-Apr;32(2):376-88. doi: 10.1177/0272989X11416870. Epub 2011 Oct 10.
7
HTA and MCDA solely or combined? The case of priority-setting in Colombia.卫生技术评估与多标准决策分析单独使用还是联合使用?以哥伦比亚的优先事项设定为例。
Cost Eff Resour Alloc. 2018 Nov 9;16(Suppl 1):47. doi: 10.1186/s12962-018-0127-6. eCollection 2018.
8
Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.避免和识别健康技术评估模型中的错误:定性研究和方法学综述。
Health Technol Assess. 2010 May;14(25):iii-iv, ix-xii, 1-107. doi: 10.3310/hta14250.
9
From Design to Evaluation: Applications of Health Technology Assessment in Myanmar and Lessons for Low or Lower Middle-Income Countries.从设计到评估:卫生技术评估在缅甸的应用及对中低收入国家的启示
Int J Technol Assess Health Care. 2019;35(6):461-466. doi: 10.1017/S0266462319000199. Epub 2019 May 17.
10
A systematic review of health technology assessment tools in sub-Saharan Africa: methodological issues and implications.撒哈拉以南非洲地区卫生技术评估工具的系统评价:方法学问题与启示
Health Res Policy Syst. 2014 Dec 2;12:66. doi: 10.1186/1478-4505-12-66.

引用本文的文献

1
Identifying Attributes for a Value Assessment Framework in China: A Qualitative Study.在中国建立价值评估框架的属性识别:一项定性研究。
Pharmacoeconomics. 2023 Apr;41(4):439-455. doi: 10.1007/s40273-022-01235-6. Epub 2023 Feb 2.
2
Proposal for capturing patient experience through extended value frameworks of health technologies.通过扩展健康技术的价值框架来获取患者体验的建议。
J Manag Care Spec Pharm. 2021 Jul;27(7):936-947. doi: 10.18553/jmcp.2021.27.7.936.
3
Potential Criteria for Frameworks to Support the Evaluation of Innovative Medicines in Upper Middle-Income Countries-A Systematic Literature Review on Value Frameworks and Multi-Criteria Decision Analyses.

本文引用的文献

1
Value Assessment Frameworks for HTA Agencies: The Organization of Evidence-Informed Deliberative Processes.卫生技术评估机构的价值评估框架:循证审议过程的组织
Value Health. 2017 Feb;20(2):256-260. doi: 10.1016/j.jval.2016.11.019.
2
The Development of the Romanian Scorecard HTA System.罗马尼亚卫生技术评估计分卡系统的发展
Value Health Reg Issues. 2016 Sep;10:41-47. doi: 10.1016/j.vhri.2016.07.006. Epub 2016 Sep 2.
3
Health technology assessment in middle-income countries: recommendations for a balanced assessment system.
支持中高收入国家创新药物评估的框架潜在标准——关于价值框架和多标准决策分析的系统文献综述
Front Pharmacol. 2020 Aug 14;11:1203. doi: 10.3389/fphar.2020.01203. eCollection 2020.
4
Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art.多准则决策分析在卫生技术评估中的应用:应对方法学挑战,提升现有技术水平。
Eur J Health Econ. 2019 Aug;20(6):891-918. doi: 10.1007/s10198-019-01052-3. Epub 2019 Apr 20.
中等收入国家的卫生技术评估:关于建立平衡评估体系的建议
J Mark Access Health Policy. 2014 Mar 11;2. doi: 10.3402/jmahp.v2.23181. eCollection 2014.
4
Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force.用于医疗保健决策的多标准决策分析——新兴良好实践:ISPOR多标准决策分析新兴良好实践工作组报告2
Value Health. 2016 Mar-Apr;19(2):125-37. doi: 10.1016/j.jval.2015.12.016. Epub 2016 Mar 7.
5
REVIEWING TRANSFERABILITY IN ECONOMIC EVALUATIONS ORIGINATING FROM EASTERN EUROPE.审视源自东欧的经济评估中的可转移性
Int J Technol Assess Health Care. 2015;31(6):434-41. doi: 10.1017/S0266462315000677.
6
Multiple Criteria Decision Analysis for Health Care Decision Making--An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force.用于医疗保健决策的多标准决策分析——简介:ISPOR多标准决策分析新兴良好实践工作组报告1
Value Health. 2016 Jan;19(1):1-13. doi: 10.1016/j.jval.2015.12.003. Epub 2016 Jan 8.
7
Health technology assessment in the Balkans: opportunities for a balanced drug assessment system.巴尔干地区的卫生技术评估:建立平衡药物评估体系的机遇
Biotechnol Biotechnol Equip. 2014 Nov 2;28(6):1181-1189. doi: 10.1080/13102818.2014.978636. Epub 2014 Nov 26.
8
Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report.经济评估在不同司法管辖区间的可转移性:药物经济学与结果研究国际协会良好研究实践工作组报告
Value Health. 2009 Jun;12(4):409-18. doi: 10.1111/j.1524-4733.2008.00489.x. Epub 2009 Jan 12.